Cancer patients can be at much higher risk for blood clots. The National Blood Clot Alliance is pleased to be participating in THE CANVAS TRIAL, a nationwide study that is seeking to compare the benefits, harms, and burdens of two different approaches to blood clot treatment in cancer patients.
THE CANVAS TRIAL is supported through a Patient-Centered Outcomes Research Institute (PCORI) award (CER-1503-29805), and is sponsored by Alliance Foundation Trials, LLC.
The official name of THE CANVAS TRIAL is “Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial).” As of Summer 2017, 76 medical centers in 16 states are actively recruiting participants, and new clinics are continuously opening THE CANVAS TRIAL.
You can find the most up-to-date list of clinics that offer THE CANVAS TRIAL by visiting here: List of Clinics.
The objective of THE CANVAS TRIAL is to compare the effectiveness of the traditional blood clot therapy of low molecular weight heparin (LMWH) and warfarin versus the new generation of direct oral anticoagulants for preventing recurrent clots in cancer patients. The information gained will empower cancer patients and physicians to make more informed choices about anticoagulation strategies to manage blood clots.
The goal is to enroll more than 900 patients in this critically important study. If you are a cancer patient who has been diagnosed with a blood clot, talk to your physician to see if participation in THE CANVAS TRIAL could be helpful to you.
You or your doctor can:
- Get more detailed information about this study here: Study Information.
- Contact THE CANVAS TRIAL team directly at: CANVAS_Coordinator@dfci.harvard.edu, 617-632-4490
